It looks like your are using Internet Explorer.

Unfortunately, Internet Explorer is an outdated browser and we do not currently support it fully. You are seeing a limited view of the meeting details below.

To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

Evidence Requirements for DTx vs Drugs

12th September @ 10:45AM EDT

Are you targeting payers as part of your market access strategy? What do you need to know about their evidence requirements for DTx?

Due to the lack of industry-wide frameworks for DTx evidence, payers' requirements are usually the same as drugs. However, drugs and DTx are very different in nature, and it is often hard to fit DTx into the traditional evidence standards. Even when DTx solutions have proven effective and safe, some payers have refused to continue covering them (for example, Aetna news). This aligns with a point raised in many HealthXL meetings; payers are sometimes more demanding with DTx compared to drugs due to the novelty of these therapies and the lack of knowledge, making it harder for DTx companies to get buy-in. Join this meeting to have a peer-to-peer conversation about:

  • Clinical evidence payers’ expectations and how to address them efficiently.
  • What health economics results do DTx companies need to show to convince payers? Most payers look at health economics data and get interested when healthcare costs reduce. What are their expectations from DTx solutions? 
  • Many startups don’t have much evidence at the beginning, but this doesn’t mean they will not be able to work with payers. How do the evidence requirements change according to DTx product maturity?
  • There is a gap in the DTx industry in terms of criteria on evidence for DTx, hence the standards used are the ones for drugs, which are usually too high for digital solutions. How can the industry work together to provide a guidance/framework widely used by the different stakeholders, including payers?

Apply to Attend

Thank you! Your submission has been received.

An invite invite link has been sent to you if you do not already have a HealthXL account.
Oops! Something went wrong while submitting the form.

Evidence Requirements for DTx vs Drugs

Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Ary Deleray
Personalized & Digital Health Strategy at Roche
Apply to Attend

Evidence Requirements for DTx vs Drugs

No items found.

Join this HealthXL Event today:

Participate in this Digital Health Sprint in order to:
- Deep dive into a topic over 2 focused sessions.
- Engage with a small group of 10 global thought-leaders throughout.
- This sprint is outcome-focused: HealthXL and participants create exclusive outputs.
- Grow your network with our break out sessions.


You actively participate in this discussion. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations.

Don't miss your opportunity to connect with senior leaders to shape the future of digital health. Because only if you are prepared now can you lead the future.

12th September @ 10:45AM EDT

Are you targeting payers as part of your market access strategy? What do you need to know about their evidence requirements for DTx?

Due to the lack of industry-wide frameworks for DTx evidence, payers' requirements are usually the same as drugs. However, drugs and DTx are very different in nature, and it is often hard to fit DTx into the traditional evidence standards. Even when DTx solutions have proven effective and safe, some payers have refused to continue covering them (for example, Aetna news). This aligns with a point raised in many HealthXL meetings; payers are sometimes more demanding with DTx compared to drugs due to the novelty of these therapies and the lack of knowledge, making it harder for DTx companies to get buy-in. Join this meeting to have a peer-to-peer conversation about:

  • Clinical evidence payers’ expectations and how to address them efficiently.
  • What health economics results do DTx companies need to show to convince payers? Most payers look at health economics data and get interested when healthcare costs reduce. What are their expectations from DTx solutions? 
  • Many startups don’t have much evidence at the beginning, but this doesn’t mean they will not be able to work with payers. How do the evidence requirements change according to DTx product maturity?
  • There is a gap in the DTx industry in terms of criteria on evidence for DTx, hence the standards used are the ones for drugs, which are usually too high for digital solutions. How can the industry work together to provide a guidance/framework widely used by the different stakeholders, including payers?
Apply to AttendRegister to AttendApply to Attend

Participants

Participants

Jordan Silberman, MD, PhD

Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.

Ary Deleray

Personalized & Digital Health Strategy at Roche

Adriano Garcez

Director, Evidence Generation & Outcomes Research, ZS Associates

Dorothy Hoffman

Access Innovation Lead, Pfizer

Ricardo C. Berrios

Executive Founder, Adhera Health Inc

Thyago Ohana

Global Digital Transformation Strategist, UCB

Anna-Maria Heidinger

Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH

Emma Carr, PhD

Co-Founder and CSO, Amara Therapeutics

Maike Schmitz

Oncology Lead, RoX Health

Simon Bock

Market Access Manager, Tiefenbacher Group

Kennetth Joseph

Gamify Pharmacist, Akili Interactive

Maxime Champain

Lead, BDH External Innovation & Alliances, Search & Evaluation, Biogen

Leticia Delgado-Herrera

Vice President, Rx+ Medical and Development Head, Astellas Pharma

Stephanie Roberts

Senior Director, National Accounts, Akili Interactive

Connie Hwang

Associate Chief Medical Officer, Twin Health

Number of Participants


Up to 12
Date  
September 12, 2022
Community

Evidence Requirements for DTx vs Drugs

Are you targeting payers as part of your market access strategy? What do you need to know about their evidence requirements for DTx?

Due to the lack of industry-wide frameworks for DTx evidence, payers' requirements are usually the same as drugs. However, drugs and DTx are very different in nature, and it is often hard to fit DTx into the traditional evidence standards. Even when DTx solutions have proven effective and safe, some payers have refused to continue covering them (for example, Aetna news). This aligns with a point raised in many HealthXL meetings; payers are sometimes more demanding with DTx compared to drugs due to the novelty of these therapies and the lack of knowledge, making it harder for DTx companies to get buy-in. Join this meeting to have a peer-to-peer conversation about:

  • Clinical evidence payers’ expectations and how to address them efficiently.
  • What health economics results do DTx companies need to show to convince payers? Most payers look at health economics data and get interested when healthcare costs reduce. What are their expectations from DTx solutions? 
  • Many startups don’t have much evidence at the beginning, but this doesn’t mean they will not be able to work with payers. How do the evidence requirements change according to DTx product maturity?
  • There is a gap in the DTx industry in terms of criteria on evidence for DTx, hence the standards used are the ones for drugs, which are usually too high for digital solutions. How can the industry work together to provide a guidance/framework widely used by the different stakeholders, including payers?
Participate in the Meeting

HealthXL Roundtables

HealthXL community meetings connect senior leaders from around the world.

Our virtual Roundtables are small, participant-led discussions where the HealthXL community discuss digital health challenges and offer solutions.

Participant-Led

HealthXL community members lead discussion on a defined topic among a maximum of 12 participants. There is no audience and no recordings, just an interactive space to reflect and share learnings.

Developed for a Busy Schedule

At 60-minutes long, roundtables are long enough for meaningful discussion among peers, but short enough to fit into busy schedules.

Check out our platform for the full HealthXL experience

Set up a free HealthXL platform account for a taste of what the community has to offer. Or talk to us about upgrading to a premium account:

  • Join any virtual and in-person events
  • Invite peers to meetings
  • Network
  • Gain full access to all articles and HealthXL reports
  • Get personalised recommendations
  • Join specialised communities in areas like DTx, AI, Clinical Trials Innovation and more
  • Full access to community insights and meeting takeaway reports

HealthXL Masterclasses

HealthXL community events give unparalleled access to digital health leaders from around the world.

Our virtual Masterclasses are 60-minute sessions where a recognised expert in their field provides an in-depth learning experience to a small audience of 8-12 members.

EXPERT-Led

HealthXL Masterclasses give you a chance to join a small group of peers and ask questions of recognised experts in a private, convenient setting.

Check out our platform for the full HealthXL experience

Set up a free HealthXL platform account for a taste of what the community has to offer. Or talk to us about upgrading to a premium account:

  • Join any virtual and in-person events
  • Invite peers to meetings
  • Network
  • Gain full access to all articles and HealthXL reports
  • Get personalised recommendations
  • Join specialised communities in areas like DTx, AI, Clinical Trials Innovation and more
  • Full access to community insights and meeting takeaway reports

HealthXL Webinars

HealthXL community events give unparalleled access to digital health experts from around the world.

Our webinars bring together panels of 3-4 global leaders from the HealthXL community to discuss core trends in digital health.

Expert Panel Discussion

Gain insights on the latest topics in digital health and ask questions of the expert panel via chat. Webinars run for 60 minutes and recordings are shared with all attendees afterwards.

Check out our platform for the full HealthXL experience

Set up a free HealthXL platform account for a taste of what the community has to offer. Or talk to us about upgrading to a premium account:

  • Join any virtual and in-person events
  • Invite peers to meetings
  • Network
  • Gain full access to all articles and HealthXL reports
  • Get personalised recommendations
  • Join specialised communities in areas like DTx, AI, Clinical Trials Innovation and more
  • Full access to community insights and meeting takeaway reports
Virtual Digital Health Meeting

Join from anywhere

No need for a high end laptop to display fancy 3D personas or interactive conference rooms: All you need is a working camera and an internet-ready device to join.

Apply to Attend now

The world of Digital Health in one Hub

Be ready for the future of Digital Health and join a community of passionate leaders, innovators and gamechangers. 

As a HealthXL member, you get access to a wealth of information, resources and connections. From daily curated news by our in-house expert team to industry reports each retailing at €2000 - you have the world of Digital Health right at your fingertips.

Our community is growing fast. Don’t miss out on your opportunity to lead the future.


Join the community here
Reports & Insights
Reports and insights shared by the DTx community
Curated
News
Daily DTx News Curated by our in-house experts
Lists & Dashboards
Interactive dashboards and downloadable organisation data

Your Digital Health Corner

All Posts
Commentary
February 16, 2024
Tess’ Top Takes from this Month’s Meetings in Digital Health: February 2024
Tess’ Top Takes from this Month’s Meetings in Digital Health: February 2024
Read More
Commentary
February 9, 2024
Is There a Space for Digital Health in the World of RNA Based Therapeutics?
Is There a Space for Digital Health in the World of RNA Based Therapeutics?
Read More
Commentary
February 2, 2024
AI in Clinical Trials: Navigating the Trial-and-Error Process
AI in Clinical Trials: Navigating the Trial-and-Error Process
Read More

Evidence Requirements for DTx vs Drugs

12th September @ 10:45AM EDT
Digital Therapeutics (DTx)

Evidence Requirements for DTx vs Drugs

12th September @ 10:45AM EDT
Digital Therapeutics (DTx)
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
LinkedIn Profile
Ary Deleray
Personalized & Digital Health Strategy at Roche
LinkedIn Profile
Adriano Garcez
Director, Evidence Generation & Outcomes Research, ZS Associates
LinkedIn Profile
Dorothy Hoffman
Access Innovation Lead, Pfizer
LinkedIn Profile
Ricardo C. Berrios
Executive Founder, Adhera Health Inc
LinkedIn Profile
Thyago Ohana
Global Digital Transformation Strategist, UCB
LinkedIn Profile
Anna-Maria Heidinger
Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH
LinkedIn Profile
Emma Carr, PhD
Co-Founder and CSO, Amara Therapeutics
LinkedIn Profile
Maike Schmitz
Oncology Lead, RoX Health
LinkedIn Profile
Simon Bock
Market Access Manager, Tiefenbacher Group
LinkedIn Profile
Kennetth Joseph
Gamify Pharmacist, Akili Interactive
LinkedIn Profile
Maxime Champain
Lead, BDH External Innovation & Alliances, Search & Evaluation, Biogen
LinkedIn Profile
Leticia Delgado-Herrera
Vice President, Rx+ Medical and Development Head, Astellas Pharma
LinkedIn Profile
Stephanie Roberts
Senior Director, National Accounts, Akili Interactive
LinkedIn Profile
Connie Hwang
Associate Chief Medical Officer, Twin Health
LinkedIn Profile

Evidence Requirements for DTx vs Drugs

Are you targeting payers as part of your market access strategy? What do you need to know about their evidence requirements for DTx?

Due to the lack of industry-wide frameworks for DTx evidence, payers' requirements are usually the same as drugs. However, drugs and DTx are very different in nature, and it is often hard to fit DTx into the traditional evidence standards. Even when DTx solutions have proven effective and safe, some payers have refused to continue covering them (for example, Aetna news). This aligns with a point raised in many HealthXL meetings; payers are sometimes more demanding with DTx compared to drugs due to the novelty of these therapies and the lack of knowledge, making it harder for DTx companies to get buy-in. Join this meeting to have a peer-to-peer conversation about:

  • Clinical evidence payers’ expectations and how to address them efficiently.
  • What health economics results do DTx companies need to show to convince payers? Most payers look at health economics data and get interested when healthcare costs reduce. What are their expectations from DTx solutions? 
  • Many startups don’t have much evidence at the beginning, but this doesn’t mean they will not be able to work with payers. How do the evidence requirements change according to DTx product maturity?
  • There is a gap in the DTx industry in terms of criteria on evidence for DTx, hence the standards used are the ones for drugs, which are usually too high for digital solutions. How can the industry work together to provide a guidance/framework widely used by the different stakeholders, including payers?
When:
12th September @ 10:45AM EDT
Apply to attend
Registration Closed

Join this group of peers and get a feel of what it's like to belong to a community of digital health gamechangers.

All meetings are limited to 10 people to allow for honest discussions, so apply fast or become a HealthXL member and get priority access to all meetings, latest industry reports and and much more.

Frequently asked questions: 

What are HealthXL Virtual Meetings?

HealthXL Virtual Meetings are private group meetings limited to 10 people across different demographic and stakeholder groups. For 75 minutes, you take a deep dive into your chosen topic and explore it from different angles. Virtual Meetings are not webinars: There is no audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And through our Community Hub, you stay up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

How can I connect with other digital health leaders?

HealthXL brings together gamechangers of digital health to support honest discussions in small, private groups. In our Community Hub, for which you can register for free, you can follow a wide range of communities across telehealth, digital therapeutics, patient engagement and more. As a full HealthXL member, you also get access to curated news, the latest insights and an expert network to connect with. Join exclusive virtual meetings to exchange strategies, viewpoints and learnings with members from like-minded yet diverse stakeholder groups.

What are the benefits of being a HealthXL community member?

As member of HealthXL, you join a community of digital health thought leaders, innovators and game changers around the world. With your membership, you get access to hundreds of insights, reports and resources. You can browse a database with over 90k healthcare organizations and view their active strategic partnerships, commercial relationships, latest funding rounds and research. Through our in-house curated digital health newsfeed, you stay informed on the most impactful news and you can regularly meet with members to share learnings, discuss the latest developments and connect with peers of different demographical stakeholder groups. Contact us today to find out about pricing options.

Through focus groups, we bring together 6-10 thought leaders and industry stakeholders in a series of virtual meetings to collaborate around a defined topic. Each meeting gives the group the opportunity to examine, analyze and collaborate with one another around a digital health topic as well as produce a shareable result.